<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Skin and Venereal Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Skin and Venereal Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский журнал кожных и венерических болезней</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9588</issn><issn publication-format="electronic">2412-9097</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">37333</article-id><article-id pub-id-type="doi">10.18821/1560-9588-2018-21-2-68-71</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">FEATURES OF EXPRESSION OF KI-67 AND NFE2L2 IN TARGET ORGANS OF MELANOMA METASTASIS IN PREMETASTATIC PHASE</article-title><trans-title-group xml:lang="ru"><trans-title>ОСОБЕННОСТИ ЭКСПРЕССИИ KI-67 И NFE2L2 В ОРГАНАХ МИШЕНЯХ МЕТАСТАЗИРОВАНИЯ МЕЛАНОМЫ В ПРЕМЕТАСТАТИЧЕСКУЮ ФАЗУ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sergeeva</surname><given-names>O. N</given-names></name><name xml:lang="ru"><surname>Сергеева</surname><given-names>О. Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Palkina</surname><given-names>N. V</given-names></name><name xml:lang="ru"><surname>Палкина</surname><given-names>Н. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Aksenenko</surname><given-names>M. B</given-names></name><name xml:lang="ru"><surname>Аксененко</surname><given-names>М. Б</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Komina</surname><given-names>A. V</given-names></name><name xml:lang="ru"><surname>Комина</surname><given-names>А. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sergeeva</surname><given-names>E. Yu</given-names></name><name xml:lang="ru"><surname>Сергеева</surname><given-names>Е. Ю</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ruksha</surname><given-names>Tatiana G.</given-names></name><name xml:lang="ru"><surname>Рукша</surname><given-names>Татьяна Геннадьевна</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, PhD, DSc., Head of Department of pathophysiology, KrasSMU n.a. prof. V.F. Voyno-Yasenetsky, Krasnoyarsk, 660022, Russian Federation</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, доцент, заведующий кафедрой патологической физиологии им. проф. В.В. Иванова ГБОУ ВПО КрасГМУ им. проф. В.Ф. Войно-Ясенецкого Минздрава России</p></bio><email>tatyana_ruksha@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2018</year></pub-date><volume>21</volume><issue>2</issue><issue-title xml:lang="en">VOL 21, NO2 (2018)</issue-title><issue-title xml:lang="ru">ТОМ 21, №2 (2018)</issue-title><fpage>68</fpage><lpage>71</lpage><history><date date-type="received" iso-8601-date="2020-07-21"><day>21</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО "Эко-Вектор"</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjsvd.com/1560-9588/article/view/37333">https://rjsvd.com/1560-9588/article/view/37333</self-uri><abstract xml:lang="en"><p>Tumor microenvironment is known to be an active participant of tumor development. Tumor microenvironment is functional cell community interacting with cancer cells and promoting proliferation, invasion and metastasis of tumor cells. In the article features of Ki-67 and NFE2L2 expression levels in target organs of melanoma metastasis in premetastatic phase are investigated. Increased Ki-67expression levels in lung tissue, liver and kidneys and decreased NFE2L2 levels in liverandkidneys can be the markers of structural and functional reorganization of melanoma metastasis target organs in premetastatic phase of melanoma development.</p></abstract><trans-abstract xml:lang="ru"><p>Известно, что опухолевое микроокружение является активным участником в развитии злокачественных новообразований. Микроокружение опухоли - это функциональная клеточная среда, взаимодействующая с опухолевыми клетками, способствующая росту, пролиферации, инвазии метастазированию опухолевых клеток. В представленной работе рассматриваются особенности уровней экспрессии транскрипционного фактора NFE2L2 и маркера пролиферации Ki-67 в органах мишенях метастазирования меланомы в преметастатическую фазу. Повышение экспрессии Ki-67 в ткани легких, печени и почек и снижение экспрессии NFE2L2 в печени и почках может свидетельствовать о реорганизации структуры и функционирования органов-мишеней метастазирования меланомы на преметастатическом этапе развития опухоли.</p></trans-abstract><kwd-group xml:lang="en"><kwd>NFE2l2</kwd><kwd>Ki-67</kwd><kwd>Pmel</kwd><kwd>melanoma</kwd><kwd>pre-metastatic phase</kwd><kwd>proliferation</kwd><kwd>antioxidant defense</kwd><kwd>target organs of metastasis</kwd><kwd>NFE2l2</kwd><kwd>Ki-67</kwd><kwd>Pmel</kwd><kwd>tumor microenvironment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>меланома</kwd><kwd>опухолевое микроокружение</kwd><kwd>преметастическая фаза</kwd><kwd>пролиферация</kwd><kwd>антиоксидантная защита</kwd><kwd>органы-мишени метастазирования</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J. Oncol. 2012; 2012: 647684. doi:10.1155/2012/647684</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Жуковец А.Г. Современные принципы и перспективы лечения меланомы кожи. Онкологический журнал. 2015; 36(4): 69-76</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Chew V., Toh H.C., Abastado J.P. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J. Oncol. 2012; 2012: 608406. doi: 10.1155/2012/608406.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Son В., Lee S., Youn H., Kim E., Kim W., Youn B. The role of tumor microenvironment in therapeutic resistance. Oncotarget. 2017; 8(3): 3933-45. doi: 10.18632/oncotarget.13907.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Zhang L., Hu Y., Xi N., Song J., Huang W., Song S., et al. Partial oxygen pressure affects the expression of prognostic biomarkers HIF-1 alpha, Ki-67, and CK20 in the microenvironment of colorectal cancer tissue. Oxid. Med. Cell. Longev. 2016; 2016: 1204715. doi: 10.1155/2016/1204715.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Park S.A., Surh Y.J. Modulation of tumor microenvironment by chemopreventive natural products. Ann. N.Y. Acad. Sci. 2017; 1401(1): 65-74. doi:10.1111/nyas.13395.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Yang L., Lin P.C. Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. Semin. Cancer Biol. 2017; 47: 185-95. doi: 10.1016/j.semcancer.2017.08.001.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Psaila B., Lyden D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer. 2009; 9(4): 285-93. doi: 10.1038/nrc2621.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Winking H., Gerdes J., Traut W. Expression of the proliferation marker Ki-67 during early mouse development. Cytogenet. Genome Res. 2004; 105(2-4): 251-6. doi: 10.1159/000078196.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Uguen A., Talagas M., Costa S., Duigou S., Bouvier S., De Braekeleer M., Marcorelles P. A p16 Ki-67 HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma. Diagn. Pathol. 2015; 10: 195. doi: 10.1186/s13000-015-0431-9.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Шишкин М.А. Особенности иммуногистохимической экспрессии маркера клеточной пролиферации Ki-67 в опухолевых и стромальных клетках колоректальной аденокарциномы. Патологiя. 2016; 37(2): 76-81</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Hintsala H.R., Haapasaari K.M., Soini Y., Karihtala P. An immunohistochemical study of NFE2L2, KEAP1 and 8-hydroxy-2’-deoxyguanosine and the EMT markers SNAI2, ZEB1 and TWIST1 in metastatic melanoma. Histol. Histopathol. 2017; 32(2): 129-36. doi:10.14670/HH-11-778.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Hintsala H.R., Jokinen E., Haapasaari K.M., Moza M., Ristimaki A., Soini Y., et al. Nrf2/Keap1 pathway and expression of oxidative stress lesions 8-hydroxy-2’-deoxyguanosine and nitrotyrosine in melanoma. Anticancer Res. 2016; 36(4): 1497-506.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Jaramillo M.C., Zhang D.D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013; 27(20): 2179-91. doi: 10.1101/gad.225680.113.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ruksha T.G., Aksenenko M.B., Papadopoulus V. Role of translocator protein in melanoma growth and progression. Arch. Dermatol. Res. 2012; 304(10): 839-45. doi: 10.1007/s00403-012-1294-5.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Costache M., Stoica A., Contolenco A., Costache D., Cirstoiu C., Simionescu O., George S. Metastatic melanoma in the femur - case report with review of literature: a pathologists point of view. Maedica (Buchar). 2014; 9(1): 62-7.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Mervic L. Time course and pattern of metastasis of cutaneous melanoma differ between men and women. PLoS One. 2012; 7(3): e32955. doi: 10.1371/journal.pone.0032955</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Damsky W.E., Rosenbaum L.E., Bosenberg M. Decoding melanoma metastasis. Cancers (Basel). 2011; 3(1): 126-63. doi:10.3390/cancers3010126.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Аксененко М.Б., Шестакова Л.А., Рукша Т.Г. Особенности метастазирования перевиваемой меланомы В16 после ингибирования активности ММП-9. Сибирский онкологический журнал. 2012; 11(1): 31-5</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Sobecki M., Mrouj K., Camasses A., Parisis N., Nicolas E., Lleres D., et al. The cell proliferation antigen Ki-67 organises heterochromatin. Elife. 2016; 5: e13722. doi: 10.7554/eLife.13722.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Ilmonen S., Hernberg М., Pyrhonen S., Tarkkanen J., Asko-Seljavaara S. Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma. Melanoma Res. 2005; 15(5): 375-81.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Bussard K.M., Mutkus L., Stumpf K., Gomez-Manzano C., Marini F.C. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016; 18(1): 84. doi: 10.1186/s13058-016-0740-2.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Beyer T.A., Xu W., Teupser D., auf dem Keller U., Bugnon P., Hildt E., et al. Impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance. EMBO J. 2008; 27(1): 212-23. doi: 10.1038/sj.emboj.7601950.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Murakami S., Motohashi H. Roles of Nrf2 in cell proliferation and differentiation. Free Radic. Biol. Med. 2015; 88(Pt B): 168-78. doi: 10.1016/j.freeradbiomed.2015.06.030.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Плешкан В.В., Зиновьева М.В., Свердлов Е.Д. Меланома: Поверхностные маркеры как первый «порт» адресной доставки терапевтических генов при многоуровневой генной терапии. Молекулярная биология. 2011; 45(3): 416-33</mixed-citation></ref></ref-list></back></article>
